Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
ANVS Stock Chart & Stats
$2.49
-$0.04(-0.79%)
At close: 4:00 PM EST
$2.49
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.11 - $5.50
Previous CloseN/A
Volume368.97K
Average Volume (3M)463.60K
Market Cap
$65.99M
Enterprise Value$33.70M
Total Cash (Recent Filing)$15.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.28
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding26,502,890
10 Day Avg. Volume423,597
30 Day Avg. Volume463,597
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.58
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$12.50Price Target Upside402.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceReductions in Tau217, total tau, brain-derived tau and neurofilament light chain suggest buntanetap may reduce neurodegeneration and support a disease‑modifying effect.
Phase 3 ExecutionFull activation of Phase 3 clinical sites and patients completing the six‑month treatment period indicate operational progress and support continued advancement of the Alzheimer's program.
Regulatory EngagementA scheduled Type C meeting with the FDA to discuss the development pathway for Parkinson's disease dementia signals active regulatory dialogue that could clarify approval requirements.
Bears Say
Cash Runway And Funding TimingCash runway through 3Q26 means the company will likely need to secure additional financing before later‑stage milestones, creating funding‑timing risk.
Development And Operational Risk From Funding ConstraintsReliance on external capital increases the risk that trial timelines, site operations or enrollment could be delayed if market conditions limit access to attractive financing.
Dilution RiskThe need for financing raises the prospect of future capital raises that could dilute existing shareholders and pressure the stock if terms are unfavorable.
Annovis Bio News
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $1.11 and its highest was $5.50 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $65.99M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is May 19, 2026 which is in 99 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Nov 12, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.377 by $0.007.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 26,502,890 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.377. Following the earnings report the stock price went up 15.166%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (402.01% Upside)
$12.50 (402.01% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.15%
12-Months-Change
Fundamentals
Return on Equity
-246.14%
Trailing 12-Months
Asset Growth
19.69%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$12.50
▲(402.01% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
15.22% Insiders
3.11% Mutual Funds
0.24% Other Institutional Investors
78.96% Public Companies and
Individual Investors